BioSpace News Archive

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced that the Company has identified effective inhibition of target gene expression in a non-clinical monkey trial for its nonalcoholic steatohepatitis treatment program.

Novavax, Inc. and Serum Institute of India Pvt. Ltd. announced that the Thailand Food and Drug Administration has granted emergency use authorization for Novavax’ protein-based vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in individuals 18 years of age and older.

US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights.

Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights.

Caribou Biosciences, Inc. announced the presentation of positive preclinical data for its allogeneic, immune-cloaked, anti-BCMA CAR-T cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma.

DEINOVE announces that its Board of Directors has approved the consolidated financial statements for the year 2021.

Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates.

Caris Life Sciences®(Caris), to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC).

PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced that their recent research will be presented at the 2022 AACR annual meeting, which will be held in New Orleans from April 8 to April 13, 2022.

Asher Biotherapeutics (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced new preclinical data further demonstrating the profile of AB248, an engineered interleukin-2 (IL-2) immunotherapy that it intends to develop for the treatment of cancer.